- In April 2024, Adherium has unveiled a new FDA-cleared Smart inhaler compatible with the AirSupra and Breztri inhalation devices. This innovative device is designed to enhance the management of chronic respiratory diseases such as asthma and COPD by providing real-time tracking and personalized data. It will enable patients and healthcare providers to monitor medication adherence and inhaler usage through a connected app, helping to optimize treatment plans. The Smartinhaler aims to improve patient outcomes by fostering better disease control, reducing exacerbations, and empowering individuals to take proactive steps in managing their respiratory conditions
- In October 2021, BreatheSuite announced FDA clearance for its device that transforms standard inhalers into smart inhalers. This innovative device enables real-time tracking of inhaler usage through a connected app, providing patients and healthcare providers with valuable data on medication adherence and frequency of use. By enhancing monitoring and offering actionable insights, the device aims to improve patient compliance and management of respiratory diseases such as asthma and COPD. It will ultimately support better disease control, reduce the risk of exacerbations, and help optimize treatment outcomes for individuals with chronic respiratory conditions
Frequently Asked Questions
Companies such as Cohero (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), GSK plc (U.K.), Propeller Health (U.S.), 3M (U.S.), Boehringer Ingelheim International GmbH (Germany) and others are the major companies in the smart inhalers market.
In April 2024, Adherium launched an FDA-cleared Smartinhaler compatible with AirSupra and Breztri devices, offering real-time tracking and personalized data to enhance management of asthma and COPD, optimize treatment, and improve patient outcomes. In October 2021, BreatheSuite received FDA clearance for a device that converts standard inhalers into smart inhalers, enabling real-time tracking through a connected app to improve medication adherence, disease control, and treatment outcomes for asthma and COPD patients.
The countries covered in the smart inhalers market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.
